CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Folic Acid-Modified Ginger-Derived Exosome-Like Nanoparticles Co-Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K-Akt Pathway Inhibition, P-gp Downregulation, and Macrophage Reprogramming.
Folic Acid-Modified Ginger-Derived Exosome-Like Nanoparticles Co-Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K-Akt Pathway Inhibition, P-gp Downregulation, and Macrophage Reprogramming.
肾细胞癌(RCC)是一种具有高度复发和转移能力的恶性肿瘤。
肾细胞癌(RCC)是一种具有高度复发和转移能力的恶性肿瘤。目前针对RCC的治疗受限于耐药性和毒副作用。本研究介绍了一种创新方法,将姜来源外泌体样纳米颗粒(GELNs)与舒尼替尼(Su)及叶酸-聚乙二醇(FA-PEG,FPD)相结合,采用主动-被动靶向策略,探索其对RCC的多机制协同治疗效果。GELNs通过差速离心结合蔗糖梯度超速离心提取。代谢组学和网络药理学预测GELNs可能通过PI3K-Akt信号通路发挥抗癌功效,随后通过体外实验得到验证。通过负载Su并用FPD进行修饰,构建了FPD-GELNs/Su。FPD修饰显著增强了肿瘤靶向性,并通过降低GELNs诱导的ABCB1/P-gp表达放大了Su敏感性。体内实验揭示,FPD-GELNs/Su通过重塑肿瘤微环境促进M1巨噬细胞极化并增加免疫T细胞浸润,从而显著抑制肿瘤生长和肺转移,且未引起明显的肝或肾毒性。本研究将网络药理学与靶向递送策略相结合,阐明了FPD-GELNs/Su通过多条通路抑制RCC进展的机制,为开发精准、低毒的纳米疗法提供了新思路。
Renal cell carcinoma (RCC) is a malignant tumor with highly recurrent and metastatic capability. The current therapies for RCC are limited by drug resistance and toxic side effects. This study introduces an innovative approach that combines ginger-derived exosome-like nanoparticles (GELNs) with sunitinib (Su) and folic acid-polyethylene glycol (FA-PEG, FPD) in an active-passive targeting strategy to explore its multi-mechanism and synergistic therapeutic effects on RCC. GELNs are extracted via differential centrifugation combined with sucrose gradient ultracentrifugation. Metabolomics and network pharmacology predicted that GELNs may exert their anticancer efficacy via the PI3K-Akt signaling pathway, which is subsequently validated through in vitro experiments. By loading Su and modifying it with FPD, FPD-GELNs/Su is constructed. The FPD modification significantly enhanced tumor targeting and amplified the Su sensitivity by reducing ABCB1/P-gp expression induced by GELNs. In vivo experiments revealed that FPD-GELNs/Su promoted M1 macrophage polarization and increased immune T-cell infiltration by remodeling the tumor microenvironment, leading to significant inhibition of tumor growth and lung metastasis without causing notable liver or kidney toxicity. This study integrates network pharmacology with targeted delivery strategies, elucidating the mechanisms by which FPD-GELNs/Su inhibits RCC progression through multiple pathways, providing new insights for the development of precise and low-toxicity nano-therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。